Quick Answer
Praxis Precision Medicines, Inc. reported Diluted EPS of $13.48 per share (loss) for fiscal year 2025.
Praxis Precision Medicines, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$13.48 | -32.0% |
| 2024 | -$10.21 | +45.4% |
| 2023 | -$18.69 | +73.2% |
| 2022 | -$69.65 | -1667.8% |
| 2021 | -$3.94 | +49.9% |
| 2020 | -$7.86 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.36 | -22.2% | -1.5% |
| June 30, 2025 | -$3.31 | -90.2% | -0.6% |
| March 31, 2025 | -$3.29 | -15.8% | -19.6% |
| September 30, 2024 | -$2.75 | -1.1% | -58.0% |
| June 30, 2024 | -$1.74 | +76.4% | +38.7% |
| March 31, 2024 | -$2.84 | +73.2% | -4.4% |
| September 30, 2023 | -$2.72 | -183.3% | +63.1% |
| June 30, 2023 | -$7.38 | -459.1% | +30.2% |
- Praxis Precision Medicines, Inc. showed a decrease of -32.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Praxis Precision Medicines, Inc.’s diluted eps has declined by 71.5% (from $7.86 per share (loss) to $13.48 per share (loss)).
- The most recent figure is from Praxis Precision Medicines, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: